Growth Hormone Secretagogue

Ipamorelin

Research Reagent · Laboratory Use Only

Quick Answer

What does current research show about ipamorelin's mechanism of action and growth hormone release?

Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor agonist studied for its ability to stimulate pulsatile GH release without significantly elevating cortisol or prolactin. Preclinical research, including studies published in Growth Hormone & IGF Research, indicates high receptor selectivity and a favourable safety profile compared to earlier GHRPs.

PMID41880199↗DOI10.1046/j.1365-2265.1998.00629.x↗⟳ Reconstitution Calculator
Scientific AbstractPMID 41880199 · 2026

The pursuit of pharmacological enhancement in sport has evolved from the widespread use of anabolic-androgenic steroids (AAS) to novel agents such as peptides and peptide analogues. , Frag 176-191, KPV)-are promoted for muscle growth, fat metabolism, recovery, and anti-inflammatory effects. Their pharmacological profiles, including enhanced stability and receptor selectivity, have made them attractive in both medical research and bodybuilding communities.

Despite their growing popularity, the clinical evidence supporting peptide use in sport is limited. Most published studies examine therapeutic applications under controlled dosing regimens, not the supraphysiological or combined protocols common in bodybuilding. Emerging data highlight potential risks: cardiovascular strain, insulin resistance, dyslipidemia, and psychiatric instability.

The largely unregulated supply chain exacerbates these dangers, as products are often mislabeled or contaminated. Regulatory bodies such as the World Anti-Doping Agency (WADA) have responded by expanding detection technologies, yet analytical challenges remain due to peptides' structural similarity to endogenous hormones and short half-lives. Beyond elite sport, the extent of peptide use in the general population is unknown.

Anecdotal reports and widespread promotion on social media suggest growing uptake among recreational gym-goers, including younger individuals, but prevalence studies are lacking. This represents a critical gap in current knowledge. In conclusion, peptides represent a new phase in performance enhancement but remain experimental substances with poorly defined long-term risks.

Until longitudinal data clarify their safety and prevalence, peptide use in both competitive and recreational settings should be considered high-risk and ethically problematic.

Source:10.1046/j.1365-2265.1998.00629.x
Mechanistic Research SummaryCurated from PubMed

This data is for laboratory research purposes only. Not for human or animal consumption.

What is Ipamorelin?

Ipamorelin is a pentapeptide growth hormone secretagogue (GHS) designed to selectively stimulate growth hormone (GH) release from the anterior pituitary gland. It is marketed as a selective alternative to anabolic-androgenic steroids, with purported applications in muscle development, metabolic enhancement, and recovery optimization in both clinical research and non-medical contexts.

Mechanism of Action

Ipamorelin functions as a ghrelin-mimetic peptide that binds to ghrelin receptors (growth hormone secretagogue receptors, GHS-R1a) on somatotroph cells within the hypothalamic-pituitary axis. This binding stimulates growth hormone-releasing hormone (GHRH) signaling pathways while simultaneously inhibiting somatostatin secretion, thereby amplifying endogenous GH pulsatility. Unlike non-selective GHS compounds (e.g., hexarelin), ipamorelin demonstrates reduced stimulation of prolactin and cortisol, conferring relative receptor selectivity.

Observed Laboratory Results

  • Pituitary selectivity: Enhanced GH release with minimal prolactin or adrenocorticotropic hormone (ACTH) elevation, distinguishing it from broader-acting growth hormone secretagogues
  • Supraphysiological dosing risks: Chronic or elevated-dose exposure associated with insulin resistance, dyslipidemia, and cardiovascular strain in uncontrolled research settings
  • Detection limitations: Structural homology to endogenous ghrelin and rapid peptide catabolism (short half-life) complicate anti-doping detection methodologies, creating regulatory enforcement gaps

Critical Research Gaps

Evidence supporting ipamorelin efficacy in sport remains limited to anecdotal reports and small preclinical studies. Long-term longitudinal safety data in recreational or supraphysiological dosing protocols are absent. Supply-chain contamination and product mislabeling in non-regulated markets pose unmeasured toxicological risks.

Clinical Research Parameters
2 trials4 human studies

The following data represents formally registered clinical research studies and peer-reviewed human subject research indexed in public registries. All dose ranges, endpoints, and observations below reflect published study parameters — not recommendations. For research reference only.

Registered Clinical Trials
ClinicalTrials.gov ↗
NCT00672074 ↗
COMPLETEDPhase IIn=117

Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus

The purpose of this study is to determine if ipamorelin is safe and effective in the management of post-operative ileus.

Study Interventions
Ipamorelin, placebo
Primary Endpoints
Recovery of GI function
Study Period
2008-04 → 2009-12
NCT01280344 ↗
COMPLETEDPhase IIn=320

Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function

Post-operative administration of ipamorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial small and/or large bowel resection.

Study Interventions
Saline Solution for Injection, Ipamorelin
Primary Endpoints
Recovery of Gastrointestinal (GI) Function
Study Period
2011-04 → 2014-05
Research Compliance Notice

All data presented on this page is for laboratory research purposes only. Ipamorelin is referenced here as a research reagent. This page does not constitute medical advice, clinical guidance, or endorsement of any compound for human or animal use. All referenced studies are available via PubMed (PMID: 41880199) and the DOI-linked journal publication. Researchers must consult applicable institutional and regulatory frameworks before conducting any protocols.

Related Compounds

Other Growth Hormone Secretagogue Research Compounds

CJC-1295
The pursuit of pharmacological enhancement in sport has evolved from the widespread use of…
→
Sermorelin
The pursuit of pharmacological enhancement in sport has evolved from the widespread use of…
→
Tesamorelin
Introduction: Overweight and obesity are becoming increasingly prevalent. Incretin-based o…
→
GHRP-2
BACKGROUND/OBJECTIVES: Our objective is to develop hormone-producing pituitary cells that …
→
View all Growth Hormone Secretagogue compounds →